uniQure N.V. (QURE)
QURE trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1590560/000110465926021898/0001104659-26-021898-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.
Profile
| Field | Value |
|---|---|
| Ticker | QURE on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | Netherlands |
| IPO year | 2014 |
| SEC CIK | 0001590560 |
| SEC industry code | Pharmaceutical Preparations |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $16.1M |
| Net income | -$199.0M |
| Operating income | -$185.3M |
| Net margin | -1236.0% |
| Operating margin | -1151.4% |
| Revenue growth | -40.6% |
| Cash | $80.2M |
| Total assets | $824.9M |
| P/E (computed) | Net income was not positive |
| P/S (computed) | 95.3× |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | No going-concern finding. | 10-Q 2026-11-04 |
| Cash and burn | $98.4M cash; operating cash flow -$48.1M a quarter. | Report 2026-09-30 |
| Shares outstanding | 70,138,860 (2026-11-02); 62,291,663 a year earlier; 47,811,479 three years earlier. | Cover page 2026-11-02 |
| Reverse splits, 3 years | None found | None on EDGAR |
| Shelf and offerings, 12 months | 0 S-3/F-3 shelf filings; 2 424B5 takedowns, 2 at the market | Latest 2026-06-24 |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | KPMG Accountants N.V., Amstelveen, Netherlands | PCAOB Form AP 2026-04-07 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $0, sold $21.8M on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q3 2026 2026-09-30 | $5.2M | -$61.2M | -$47.8M | $98.4M | $50.3M | $20.2M | 10-Q 2026-11-04 |
| Q2 2026 2026-06-30 | $5.8M | -$81.1M | -$28.6M | $413.0M | $50.1M | $18.7M | 10-Q 2026-07-29 |
| Q1 2026 2026-03-31 | $3.6M | -$53.5M | -$38.2M | $140.0M | $49.9M | $18.1M | 10-Q 2026-05-05 |
| Q4 2025 2025-12-31 | $5.6M | -$37.1M | -$77.6M | $80.2M | $71.9M | $16.1M | 10-K 2026-03-02 |
| Q3 2025 2025-09-30 | $3.7M | -$80.5M | -$16.4M | $597.1M | $51.9M | $15.8M | 10-Q 2026-11-04 |
| Q2 2025 2025-06-30 | $5.3M | -$37.7M | -$39.9M | $253.8M | $51.8M | $14.3M | 10-Q 2026-07-29 |
| Q1 2025 2025-03-31 | $1.6M | -$43.6M | -$44.1M | $217.2M | $51.6M | $20.2M | 10-Q 2026-05-05 |
| Q4 2024 2024-12-31 | $5.2M | -$73.3M | -$52.8M | $158.9M | $66.0M | $27.1M | 10-K 2026-03-02 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | 424B5 | 2026-06-24 |
| Latest annual report | 10-K | 2026-03-02 |
| Latest quarterly / interim | 10-Q | 2026-11-04 |
| Latest current report FORM 8-K | 8-K | 2026-11-04 |
| Latest proxy | DEFA14A | 2026-04-27 |
Source: SEC EDGAR submissions feed, 955 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | +9.7% |
| 1 month | +11.9% |
| 3 months | -49.4% |
| Year to date | -0.5% |
| 1 year | -21.5% |
| From 52-week high | -53.4% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| PGEN | Precigen Inc. | $4.30 | -5.29% | $1.5B |
| SLS | SELLAS Life Sciences Group Inc. | $7.47 | -4.96% | $1.5B |
| ADRX | ADARx Pharmaceuticals Inc. | $14.00 | -1.41% | $1.6B |
| KRSA | Korsana Biosciences Inc. | $32.68 | +3.25% | $1.5B |
| RAPP | Rapport Therapeutics Inc. | $24.82 | -5.09% | $1.5B |
| NRIX | Nurix Therapeutics Inc. | $14.73 | -4.84% | $1.6B |
| PCRX | Pacira BioSciences Inc. | $36.48 | +0.05% | $1.5B |
| ANIP | ANI Pharmaceuticals Inc. | $70.89 | -0.77% | $1.6B |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier